![]() We then licensed Linebacker 1 and 2, compounds that have multi-billion dollar potential as cancer co-therapies. Our first licensing efforts included Equivir (OTC) and Equivir G (Rx), broad-based anti-viral compounds. ![]() In 2022, we formed ProPhase BioPharma to license, develop and commercialize drugs and compounds with enormous potential. We are rapidly developing into a true diagnostics and genomics company that will leverage our CLIA laboratories for COVID-19 Testing, whole genome sequencing, and a wide variety of diagnostic testing. For more information on how our historical price data is adjusted see the Stock Price. In 2021, we acquired Nebula Genomics and formed ProPhase Precision Medicine. The average ProPhase Labs stock price for the last 52 weeks is 7.45. In 2020, we pivoted to build out state-of-the-art CLIA labs for COVID-19 diagnostic testing. Historically, we have been a diversified medical science and technology company that delivers breakthrough, clinically shown supplements, and OTC manufacturing. It also engages in the research and development of potential over-the-counter drugs.For almost 30 years, ProPhase has been relentlessly focused on enhancing wellness and improving health. ProPhase makes and distributes a range of homeopathic and health products. ![]() "We believe ProPhase faces significant challenges by remaining as a standalone entity, including lack of scale, an unsustainable financial model and limited liquidity," Matrixx chief executive Marylou Arnett said. The stock has a market capitalization of 162.91 million, a PE. Matrixx, also a maker of cold and sinus medications, said its revised all-cash offer is not contingent on financing and is "highly attractive to ProPhase shareholders." The company’s fifty day moving average price is 11.28 and its 200-day moving average price is 8.56. Shares of ProPhase gained 10 cents to hit $1.45 on the Nasdaq on Tuesday - well below the newest bid price.īased on ProPhase's 14.84 million outstanding common shares, the deal is pegged somewhere around $23.7 million. Prophase Labs General Information Want detailed data on 3M+ companies Stock Performance Financials Summary Valuation & Funding Want to dig into this. The Company continues to provide traditional CLIA. The revised offer is a 19 per cent premium to ProPhase's Monday closing price of $1.35. (Nasdaq: PRPH) (ProPhase) is a diversified diagnostics, genomics and biotech company that seeks to leverage its CLIA lab services to provide whole genome sequencing and research direct to consumers and build a genomics data base to be used for further research. The Diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the. Its operating segments include Diagnostic services and Consumer products. Matrixx's new bid of $1.60 per share tops its May offer for the cold remedy company of $1.40 per share. PRPH Institutional Ownership and Shareholders - ProPhase Labs Inc (NASDAQ) Stock Average Portfolio Allocation, - change of MRQ Shares Outstanding, shares. ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Cold-Eeze maker ProPhase Labs Inc.'s ( NASDAQ:PRPH) stock popped after Matrixx Initiatives raised its takeover offer for the company by 14.3 per cent.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |